October 10, 2017
Clinical Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Additional Nonclinical Data Show APX001 is Effective Against a Broad Range of Pathogenic Fungi, Including Deadly Candida auris SAN DIEGO – October 9, 2017 – Amplyx Pharmaceuticals, a company developing novel antimicrobial agents for life-threatening fungal infections, today announced that it presented results from two Phase 1 studies of APX001,...


How it can help to give an electric shock  
17. July 2018
1,000 old skeletons to provide new knowledge about brain disorders
17. June 2018
Lundbeck Foundation’s magazine out now
1. June 2018


Lundbeckfonden Ventures

Lundbeckfonden Emerge